Menu
Recruiting NCT07220096

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

Observational Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Survey.
Who it may be relevant to
Registry conditions: Lung Cancer. Basic parameters: 18 years — 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this research study is to learn about: The effect of enrolling in the YOLC program on patient satisfaction with care provided, The needs of patients younger than 50 with lung cancer and their family, and The impact of participating in peer support networks on these patients.

Detailed description

Primary Objectives:

1. To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided. 2. To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway. 3. To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints.

Secondary Objectives:

1. To determine whether enrollment in a dedicated program (YOLC) results in improved patient satisfaction with care provided. 2. To characterize the distinct needs of patients under age 50 diagnosed with lung cancer as well as those of their families, and how these needs may change over time throughout the care pathway. 3. To evaluate the impact of participation in peer support networks and whether it has a beneficial effect on the primary and secondary endpoints. 4. Overall survival, defined by time from diagnosis to death from any cause 5. Clinical trial enrollment, defined by participation in any therapeutic clinical trial related to lung cancer treatment after diagnosis 6. Completion of multi-disciplinary consultations, defined by patients completing consultations with at least one other specialist other than a thoracic medical oncologist or thoracic surgeon from time of initial consultation for the YOLC Program 7. Quality of life, as defined by FACT-LUNG 8. Financial toxicity, as defined by patient-reported financial burden, including out-of-pocket costs, insurance coverage issues, and impact of overall financial well-being (measured using validated financial toxicity scale such as COST-FACIT

Interventions

  • Other Survey
    Participants will complete an intake survey and repeat surveys at the following time points: * Baseline * 3 months * 6 months * 9 months * 12 months * 18 months * 24 months * 36 months * 48 months * 60 months

Primary outcome measures

  • Participant satisfaction with care [Time frame: Through study completion; an average of 5 year]

Eligibility criteria

Inclusion criteria

  • Age greater than 18 years and under 50 years
  • Histologic confirmation of NSCLC
  • Able to complete an English-language survey independently or with the assistance of a native-language interpreter
  • Pregnant women- may be enrolled due to age range of subjects. (Low risk)

Exclusion criteria

  • Medical, psychiatric, cognitive, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the study protocol or to complete the study.
  • The following special patient population will be excluded from study group:
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners
  • Cognitively-impaired adults

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • The University of Texas M. D. Anderson Cancer Center — Houston

Identifiers

NCT: NCT07220096 · 2025-0646 · NCI-2025-07304

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗